|
|
| Shop 1: | DFH PHARMACY - 10% discount coupon DFH10
|
| Shop 2: | MEDS FOR SALE - 5% discount coupon 5OFF
|
| Prices: | from $0.81 per pill
|
| Forms: | 200 mg tablets
|
| Quantity: | 30-360 pills
|
| Type: | Pirfenex brand, Pirfeheal brand, Esbriet generic
|
| Payment: | Visa, Mastercard, AmEx, Cryptocurrencies
|
| Delivery: | Regular and express mail services
|
| Shipping: | Worldwide, including USA, UK, Europe, Canada, Australia |
Indications and usage:
Esbriet (Pirfenidone) is an immunosuppressive agent from pyridone chemical class. It is indicated for the treatment of idiopathic pulmonary fibrosis (IPF), chronic liver fibrosis.
Dosage and administration:
Take pirfenidone with food.
Recommended dosage: 801 mg three times daily (2403 mg/day).
Upon initiation of treatment, titrate to the full dosage of 2403 mg/day over a 14-day period.
Consider temporary dosage reduction, treatment interruption, or discontinuation for management of adverse reactions.
Prior to treatment, conduct liver function tests.
Dosage forms and strengths:
Esbriet (Pirfenidone) capsules 267 mg, tablets 267 mg and 801 mg.
Pirfenex (Pirfenidone) film-coated tablets 200 mg and 400 mg.
Contraindications:
None.
Warnings and precautions:
Elevated liver enzymesand drug-induced liver injury: ALT, AST, and bilirubin elevations have occurred with Esbriet including cases of drug-induced liver injury. In the postmarketing setting, non-serious and serious cases of drug-induced liver injury, including severe liver injury with fatal outcomes, have been reported. Monitor ALT, AST, and bilirubin before and during treatment. Temporary dosage reductions or discontinuations may be required.
Photosensitivity and rash: photosensitivity and rash have been noted with Pirfenidone (Esbriet). Avoid exposure to sunlight and sunlamps. Wear sunscreen and protective clothing daily. Temporary dosage reductions or discontinuations may be required.
Gastrointestinal disorders: nausea, vomiting, diarrhea, dyspepsia, gastro-esophageal reflux disease, and abdominal painhave occurred with Pirfenidone. Temporary dosage reductions or discontinuations may be required.
Overdosage:
There is limited clinical experience with overdosage by pirfenidone. Multiple dosages of Esbriet up to amaximum tolerated dose of 4005 mg per day were administered as five 267 mg capsules three times daily to healthy adult volunteers over a 12-day dose escalation.
In the event of a suspected overdosage, appropriate supportive medical care should be provided, including monitoring of vital signs and observation of the clinical status of the patient.
Side effects, adverse reactions:
The most common adverse reactions ( >= 10%) of pirfenidone are nausea, rash, upper respiratory tract infection, abdominal pain, diarrhea, headache, fatigue, dyspepsia, vomiting, dizziness, anorexia, sinusitis, insomnia, weight decreased, gastro-esophageal reflux disease, and arthralgia.
To report suspected side effects of Pirfenex (Pirfenidone) 200 mg tablets, contact Cipla pharmaceutical company.
To report suspected adverse reactions of Esbriet (Pirfenidone) pills, contact Genentech Inc. or your local FDA.
Drug interactions:
Moderate (e.g., ciprofloxacin) and strong inhibitors of CYP1A2 (e.g., fluvoxamine) increase systemic exposure of pirfenidone and may alter the adverse reaction profile of Esbriet. Discontinue fluvoxamine prior to administration of this drug or reduce to 267 mg three times a day. Consider dosage reduction with use of ciprofloxacin.
Use in specific populations:
Pregnancy: the data with this medication use in pregnant women are insufficient to inform on drug associated risks for major birth defects and miscarriage.
Lactation: no information is available on the presence of pirfenidone in human milk, the effects of the drug on the breastfed infant, or the effects of the drug on milk production.
Pediatric use: safety and effectiveness of Esbriet in pediatric patients have not been established.
Geriatric use: no overall differences in safety or effectiveness were observed between older and younger patients. No dosage adjustment is required based upon age.
Hepatic impairment: monitor for adverse reactions and consider dosagemodification or discontinuation of Esbriet as needed. This medication is not recommended for use in patients with severe hepatic impairment. Renal impairment: monitor for adverse reactions and consider dosage modification or discontinuation of Pirfenidone as needed. This medicine is not recommended for use in patients with end stage renal disease on dialysis.
Smokers: decreased exposure has been noted insmokers which may alter the efficacy profile of Esbriet (Pirfenidone) capsules and tablets.
Where to buy pirfenidone online:
To purchase Pirfenex, Esbriet (Pirfenidone) 200 mg tablets from reliable online pharmacies and drugstores at low prices please use resources described above on this webpage.
Here is a list of popular medications containing pirfenidone as a main active pharmaceutical ingredient; their trade names, forms, doses, companies - manufacturers, distributors, suppliers, researchers and developers:
| Trade name of the drug |
Pharmaceutical forms and doses |
Companies |
| Esbriet |
Capsules; Oral; 267 mgTablets; Oral; 267 mg, 801 mg |
RocheAndersonBrecon PharmaceuticalsCatalentGenentechHaemato PharmIntermune |
| Pirespa |
Tablets; Oral; 200 mg |
Shionogi |
| Pirfenex |
Tablets, Film-Coated; Oral; 200 mg, 400 mg |
Cipla |
|
 |
|
|
E-MAIL NEWSLETTER
|
|
Sign up for occasional updates from the Centre for Integral Economics.
|
|
|
